Budesonide for induction of remission in Crohn's disease-Reference-Cited by-同舟云学术

Budesonide for induction of remission in Crohn's disease

Published:2015-06-03 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Rezaie Ali¹,Kuenzig M Ellen²³,Benchimol Eric I⁴⁵,Griffiths Anne Marie⁶,Otley Anthony R⁷,Steinhart A Hillary⁸,Kaplan Gilaad G²³,Seow Cynthia H²³

Affiliation:

1. Cedars-Sinai Medical Center; Department of Medicine; Los Angeles California USA 90048

2. University of Calgary; Department of Medicine; Calgary AB Canada

3. University of Calgary; Department of Community Health Sciences; Calgary AB Canada

4. The Children's Hospital of Eastern Ontario; CHEO Inflammatory Bowel Disease Centre, Division of Gastroenterology Hepatology & Nutrition; 401 Smyth Road Ottawa Ontario Canada K1H 8L1

5. University of Ottawa; Department of Pediatrics, School of Epidemiology, Public Health and Preventive Medicine; Ottawa Ontario Canada

6. The Hospital for Sick Children; Division of Gastroenterology, Hepatology & Nutrition; 555 University Ave. Toronto ON Canada M5G 1X8

7. IWK Health Centre; Head, Division of Gastroenterology; 5850 University Avenue Halifax NS Canada B3K 6R8

8. Mount Sinai Hospital; Department of Medicine, Division of Gastroenterology; Room 445, 600 University Avenue Toronto ON Canada M5G 1X5

Publisher

Wiley

Subject

Pharmacology (medical)

Reference78 articles.

1. Budesonide versus prednisone in the treatment of active Crohn's disease;Bar-Meir;Gastroenterology,1998

2. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group;Campieri;Gut,1997

3. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease;D'Haens;Aliment Pharmacol Ther,1998

4. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial;Escher;Eur J Gastroenterol Hepatol,2004

5. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group;Greenberg;N Engl J Med,1994

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08

2. Budesonide in Liver Immunology: A Therapeutic Opportunity in Liver Transplantation;Current Transplantation Reports;2024-07-11

3. Recomendaciones basadas en el manejo de pacientes con diagnóstico de enfermedad de Crohn en el contexto peruano. Documento de posición de la Asociación Peruana para el Estudio del Intestino (ASPEIN);Revista de Gastroenterología del Perú;2024-06-26

4. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment;Journal of Crohn's and Colitis;2024-06-15

5. Budesonide Induces Favourable Histologic and Symptomatic Recovery in Patients with Non-responsive and Refractory Coeliac Disease When Given in an Open Capsule Format;Digestive Diseases and Sciences;2024-04-29